Kenvue: CFO Sold at Peak While Institutions Quietly Bought
Kenvue's CFO sold 3,700 shares at $18.11 on June 10, 2026, just before Q2's first earnings miss in four quarters (EPS $0.31 vs. $0.319 consensus). Yet Readystate Asset Management and Nykredit have sin
Institutions Buy KVUE Despite Miss and Deal Setback
NEW YORK, September 7 —
Kenvue Inc. (KVUE) delivered a contradiction: the CFO sold in June after the company's strongest quarterly beat, Q2 then missed for the first time in four quarters, a Kimberly-Clark deal reportedly stalled, yet two institutions recently bought roughly 454,000 combined shares above the CFO's price. Someone is pricing in a recovery the results have not shown.
- Q2 EPS of $0.31 missed the consensus by 2.8%, snapping three straight quarters of double-digit beats.
- CFO Howlett's Form 4 shows 3,700 shares sold at $18.11 on June 10, 2026, after Q1's +23.1% EPS beat.
- Readystate Asset Management and Nykredit recently disclosed combined purchases of 454,719 KVUE shares; stock now trades at $18.74.
The CFO Timed the Peak
Heather Howlett, Kenvue's CFO, sold 3,700 shares at $18.11 on June 10, 2026, per a Form 4 filing. She sold after Q1 2026 delivered the streak's strongest beat: +23.1% upside to consensus, $0.32 actual against a estimate, and before the August 6 8-K disclosed the Q2 miss. At roughly $67,000, the position is modest, and insiders hold just 0.1% of shares. But the directional signal holds: the CFO sold at the peak of earnings momentum in a company whose OTC medicines, including Tylenol, Motrin, Benadryl, and Zyrtec, had been driving the outperformance.
Fundamental Value, Minus the Catalyst
Readystate Asset Management and Nykredit disclosed purchases of 200,000 and 254,719 KVUE shares respectively, accumulated at prices including levels above $18.11. Kenvue's Neutrogena skin care, Listerine oral care, and BAND-AID wound care add to a 21,780-person operation generating billion in trailing free cash flow on $15.41 billion in revenue and a 58.4% gross margin. At 15.1x forward earnings, the valuation does not demand growth the business is not currently delivering. Per a Seeking Alpha report, the Kimberly-Clark bid that may have been supporting the stock reportedly hit an obstacle.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| KVUE | $36.0B | 15.1x | +1.7% |
| KDP | $44.3B | 12.9x | +18.0% |
| AMCR | $20.9B | 10.4x | +9.9% |
| GEHC | $31.1B | 12.7x | -11.9% |
| HLN | $42.2B | 15.4x | -1.4% |
| TFC | $63.1B | 10.4x | +12.3% |
The Test Is Q3
Kenvue carries $8.61 billion in total debt against $1.11 billion in cash, a balance sheet that makes free cash flow durability non-optional. The consensus price target of $19.50 sits $0.76 above current levels, leaving little cushion if earnings momentum fails to recover. With the acquisition catalyst reportedly stalled, the next checkpoint is Q3: a second consecutive miss extends the trend and validates the CFO's June read; a return to consensus beats vindicates the institutions. Stress-test the assumptions with the DCF calculator, or run the free Kenvue Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Kenvue stock miss Q2 earnings?
Kenvue reported Q2 EPS of $0.31, missing the $0.319 consensus by 2.8%. This was the company's first miss in four consecutive quarters, ending a streak of double-digit beats that had supported share momentum in the prior period.
Did insiders or institutions buy KVUE after Q2?
The CFO sold 3,700 shares at $18.11 in June, but Readystate Asset Management and Nykredit subsequently purchased a combined 454,719 shares at prices including levels above the CFO's sale price, with the stock currently at $18.74.
What's the Kimberly-Clark deal about?
Per reporting, a Kimberly-Clark bid for Kenvue reportedly hit an obstacle. The deal was seen as potentially supportive for the stock, but its stall removes a near-term catalyst.
What brands does Kenvue own?
Kenvue manufactures Tylenol, Motrin, Benadryl, Zyrtec (OTC medicines), Neutrogena skin care, Listerine oral care, and BAND-AID wound care.
What is Kenvue worth today?
At 15.1x forward earnings, the valuation does not demand growth the business isn't currently delivering. The consensus price target of $19.50 sits just $0.76 above the current stock price of $18.74, leaving little cushion if earnings momentum fails to recover.
Two institutional investors recently disclosed combined purchases of roughly 454,000 Kenvue shares at a price above what the company's own CFO received when she sold in June — weeks before Kenvue posted its first earnings miss in four quarters and reports surfaced that a potential Kimberly-Clark acquisition bid had hit an obstacle. The question is what the buyers see that the CFO did not.